10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies

Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.

NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics

Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG).

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.

OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap.

10x Genomics: Unveiling The Investment Potential

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Arias - Stifel Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Salem Salem - Barclays Tejas Savant - Morgan Stanley John Sourbeer - UBS Mason Carrico - Stephens Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Rachel Vatnsdal - JPMorgan Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.

10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript

PLEASANTON, Calif. , Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023.

10x Genomics Reports Third Quarter 2023 Financial Results

PLEASANTON, Calif. , Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25th Annual Conference on Tuesday, November 14, at 10:00 a.m.

10x Genomics to Present at the Stephens 25th Annual Conference

Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions PLEASANTON, Calif. , Oct. 26, 2023 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the 10x Xenium Analyzer was used in a study recently published on bioRxiv characterizing radiation-resistance mechanisms of diffuse midline gliomas (DMGs).

Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

PLEASANTON, Calif. , Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023.

10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023

UPC Denies Second Preliminary Injunction Request; Prior Injunctions Against NanoString's CosMx Products in Europe Remain in Full Effect PLEASANTON, Calif. , Oct. 10, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") has declined to issue a second preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) based on European Patent 2 794 928 B1 ("the EP 928 patent," docket No 459996/2023).

10x Genomics Comments on Second UPC Preliminary Injunction Decision

Second Injunction Issued Against CosMx PLEASANTON, Calif. , Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023).

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows PLEASANTON, Calif. , Sept. 14, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling.

10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance in both single-cell and spatial biology portfolios. Despite challenges in the Chinese market and a decrease in gross margin, 10x Genomics remains well-positioned for growth with a strong cash position.

10x Genomics: Recent Performance Amplifies My Bullish Conviction

Researchers uncover mechanisms behind divergent responses to immune checkpoint blockade between primary and metastatic brain tumors PLEASANTON, Calif. , Sept. 5, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its technologies were used in a study published in the Journal of Clinical Investigation to explain why immune checkpoint blockade, a type of immunotherapy, is more effective for treating cancers that spread to the brain than it is for cancers that originate in the brain, like glioblastoma.

Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others

PLEASANTON, Calif. , Aug. 30, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 8:50 a.m.

10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale PLEASANTON, Calif. , Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch.

10x Genomics Surpasses 100 Xenium Analyzer Shipments

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

10X Genomics, Inc. (NASDAQ:TXG ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Cassie Corneau - Manager, IR and Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Justin McAnear - CFO Conference Call Participants Patrick Donnelly - Citigroup Daniel Arias - Stifel, Nicolaus & Company Kyle Boucher - TD Cowen Michael Ryskin - Bank of America Merrill Lynch Tejas Savant - Morgan Stanley Matthew Larew - William Blair & Company Mason Carrico - Stephens Inc. Tianqi Hang - UBS Kyle Mikson - Canaccord Genuity Justin Bowers - Deutsche Bank Noah Burhance - JPMorgan Chase & Co. Operator Hello, everyone. Welcome to the 10x Genomics Second Quarter 2023 Earnings Conference Call.

10X Genomics, Inc. (TXG) Q2 2023 Earnings Call Transcript

10x Genomics beat second-quarter sales forecasts Thursday, though losses came in steeper than expected. TXG stock slid in late action.

Buy-Zone-Adjacent 10x Genomics Tops Sales Views, But There's A Caveat

PLEASANTON, Calif. , Aug. 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023.

10x Genomics Reports Second Quarter 2023 Financial Results

Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation.

Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation

PLEASANTON, Calif. , July 13, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023 after market close on Thursday, August 3, 2023.

10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023

Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells PLEASANTON, Calif. , July 5, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its single-cell genomic technologies were used in a study published in the journal Nature Medicine about new gene signatures that explain why some children with leukemia have longer remission after CAR T-cell therapy.

CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing some analysis, I believe the company's growth record and prospects outweigh the risks at this point. I am moving it up on my watch list. The medicines of the future will rely upon the technology that 10x is involved in. Clearly, this could lead to a massive market opportunity for the company.

10x Genomics: Growth Outweighing The Risks

Illumina

Natera

The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations.

News for 10X Genomics Stock (TXG)